Provided by Tiger Trade Technology Pte. Ltd.

HENGRUI PHARMA

49.220
-0.980-1.95%
Volume:2.60M
Turnover:127.13M
Market Cap:326.67B
PE:35.65
High:50.200
Open:50.200
Low:48.020
Close:50.200
52wk High:94.869
52wk Low:43.020
Shares:6.64B
HK Float Shares:258.00M
Volume Ratio:0.83
T/O Rate:1.01%
Dividend:0.23
Dividend Rate:0.48%
EPS(LYR):1.381
ROE:12.46%
ROA:7.02%
PB:4.33
PE(LYR):35.65
PS:8.91

Loading ...

Jiangsu Hengrui Pharmaceuticals Completes Initial Share Repurchase, Investing 14.5 Million Yuan

Stock News
·
Sep 17

HENGRUI PHARMA: BlackRock, Inc. Acquires Shares, Long Position Rises to 7.68%

HK Disclosure
·
Sep 17

Hong Kong Stock Market Update: Hengrui Pharma Surges Nearly 4% in Late Trading Following Dual Clinical Trial Approvals

Stock News
·
Sep 16

China's Jiangsu Hengrui Climbs on Clinical Trial Approval for Stroke Drug

Reuters
·
Sep 16

Hengrui Pharmaceuticals' Unit Gets Nod to Trial Recaticimab Injection

MT Newswires Live
·
Sep 16

Movement Alert|HENGRUI PHARMA Rises 3.01% in Regular Trading, Dense Pipeline Milestones Boost Market Sentiment

Market Focus
·
Sep 16

BlackRock's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Increases to 7.17% on Sept 10 from 6.56% - HKEX

THOMSON REUTERS
·
Sep 15

Jiangsu Hengrui Secures Green Light for HRS-4139 Tablet Clinical Trials

Stock News
·
Sep 15

Chinese Drug Regulator Accepts Hengrui Pharmaceuticals Unit's Marketing Application for SHR-2004 Injection

MT Newswires Live
·
Sep 15

Big Pharma is Pouring Billions into China's Biotechs

Dow Jones
·
Sep 14

Movement Alert|HENGRUI PHARMA Rises 3.2% in Regular Trading, Core ADC Pipeline Drug Included in Breakthrough Therapy Designation List

Market Focus
·
Sep 14

Hengrui Pharmaceuticals' Lung Cancer Drug Included in China's Breakthrough Therapy Designation List

MT Newswires Live
·
Sep 14

Hengrui Pharma Gets China Nod for Two Indications of Hetrombopag Olamine Tablets

MT Newswires Live
·
Sep 10

Jiangsu Hengrui Pharmaceuticals Co - Nmpa Approves Two New Indications for Hetrombopag Olamine Tablets

THOMSON REUTERS
·
Sep 10

Jiangsu Hengrui Pharmaceuticals Secures Regulatory Nod for Two New Indications of Hetrombopag Olamine Tablets

Stock News
·
Sep 10

Movement Alert|HENGRUI PHARMA Falls 3.13% in Regular Trading, Broad Pharma Sector Selloff Weighs on Shares Despite Drug Application Progress

Market Focus
·
Sep 10

China Accepts Hengrui Pharma Unit's Marketing Application for Diabetes Drug

MT Newswires Live
·
Sep 10

AH Share Premium Rankings as of September 9 Trading Close

Stock News
·
Sep 09

Hengrui Pharma Sets 24 Sep 2026 EGM to Vote on Dual Employee Share Schemes and 10% H-Share Buyback Mandate

Bulletin Express
·
Sep 08

Hengrui Pharma Seeks Approval for 2026 Dual-Class Incentive Plans and 10% H-Share Buy-Back Authority

Bulletin Express
·
Sep 08